Free Trial

Cardio Diagnostics Q3 2023 Earnings Report

Cardio Diagnostics logo
$0.61 +0.08 (+14.80%)
As of 04:00 PM Eastern

Cardio Diagnostics EPS Results

Actual EPS
-$0.17
Consensus EPS
-$0.39
Beat/Miss
Beat by +$0.22
One Year Ago EPS
N/A

Cardio Diagnostics Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Cardio Diagnostics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Cardio Diagnostics Earnings Headlines

24/7 Automated Profits in Crypto
What if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast world of passive crypto income, where you set up a dependable income stream that works for you, whether you're at your computer or living your life.
Top 12 AI Stock News and Ratings Dominating Wall Street
See More Cardio Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cardio Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardio Diagnostics and other key companies, straight to your email.

About Cardio Diagnostics

Cardio Diagnostics (NASDAQ:CDIO) develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

View Cardio Diagnostics Profile

More Earnings Resources from MarketBeat